Multimodal action of MAS activation for systemic cancer cachexia therapy

Research output: Contribution to journalReview article

Abstract

Cancer cachexia remains a largely intractable, deadly condition for patients with no approved, effective therapies. However, research progress over the past few decades demonstrates that cachexia is a disease with specific, targetable mechanisms. New work by Murphy and colleagues in this issue of Cancer Research suggests that activation of the alternative renin–angiotensin system with the nonpeptide Mas receptor agonist AVE 0991 holds promise for reducing muscle wasting in cancer. Their cell studies demonstrate on-target activity in skeletal muscle cells, whereas their mouse results suggest potentially more important systemic effects.

Original languageEnglish (US)
Pages (from-to)699-700
Number of pages2
JournalCancer Research
Volume79
Issue number4
DOIs
StatePublished - Feb 15 2019

Fingerprint

Cachexia
Neoplasms
Research
Muscle Cells
Skeletal Muscle
Therapeutics
Muscles

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Multimodal action of MAS activation for systemic cancer cachexia therapy. / Rupert, Joseph E.; Koniaris, Leonidas; Zimmers, Teresa.

In: Cancer Research, Vol. 79, No. 4, 15.02.2019, p. 699-700.

Research output: Contribution to journalReview article

@article{65d08bdc32a141cab6e4a7e8ee579ae9,
title = "Multimodal action of MAS activation for systemic cancer cachexia therapy",
abstract = "Cancer cachexia remains a largely intractable, deadly condition for patients with no approved, effective therapies. However, research progress over the past few decades demonstrates that cachexia is a disease with specific, targetable mechanisms. New work by Murphy and colleagues in this issue of Cancer Research suggests that activation of the alternative renin–angiotensin system with the nonpeptide Mas receptor agonist AVE 0991 holds promise for reducing muscle wasting in cancer. Their cell studies demonstrate on-target activity in skeletal muscle cells, whereas their mouse results suggest potentially more important systemic effects.",
author = "Rupert, {Joseph E.} and Leonidas Koniaris and Teresa Zimmers",
year = "2019",
month = "2",
day = "15",
doi = "10.1158/0008-5472.CAN-18-3910",
language = "English (US)",
volume = "79",
pages = "699--700",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Multimodal action of MAS activation for systemic cancer cachexia therapy

AU - Rupert, Joseph E.

AU - Koniaris, Leonidas

AU - Zimmers, Teresa

PY - 2019/2/15

Y1 - 2019/2/15

N2 - Cancer cachexia remains a largely intractable, deadly condition for patients with no approved, effective therapies. However, research progress over the past few decades demonstrates that cachexia is a disease with specific, targetable mechanisms. New work by Murphy and colleagues in this issue of Cancer Research suggests that activation of the alternative renin–angiotensin system with the nonpeptide Mas receptor agonist AVE 0991 holds promise for reducing muscle wasting in cancer. Their cell studies demonstrate on-target activity in skeletal muscle cells, whereas their mouse results suggest potentially more important systemic effects.

AB - Cancer cachexia remains a largely intractable, deadly condition for patients with no approved, effective therapies. However, research progress over the past few decades demonstrates that cachexia is a disease with specific, targetable mechanisms. New work by Murphy and colleagues in this issue of Cancer Research suggests that activation of the alternative renin–angiotensin system with the nonpeptide Mas receptor agonist AVE 0991 holds promise for reducing muscle wasting in cancer. Their cell studies demonstrate on-target activity in skeletal muscle cells, whereas their mouse results suggest potentially more important systemic effects.

UR - http://www.scopus.com/inward/record.url?scp=85061600921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061600921&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-18-3910

DO - 10.1158/0008-5472.CAN-18-3910

M3 - Review article

C2 - 30770364

AN - SCOPUS:85061600921

VL - 79

SP - 699

EP - 700

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 4

ER -